Jaén-Moreno María José, Rico-Villademoros Fernando, Ruiz-Rull Cristina, Laguna-Muñoz David, Del Pozo Gloria Isabel, Sarramea Fernando
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Departamento de Ciencias Morfológicas y Sociosanitarias, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain.
COPD. 2023 Dec;20(1):31-43. doi: 10.1080/15412555.2022.2154646.
A systematic review aimed to investigate the association between schizophrenia and bipolar disorder and chronic obstructive pulmonary disease (COPD), its prevalence and incidence, potential factors associated with its occurrence and its impact on mortality among these patients. We performed the literature search in PubMed, Scopus and PsycInfo from inception to February 2022 and identified 19 studies: ten cross-sectional, 5 that included cross-sectional and longitudinal analyses, and 4 retrospective cohort studies. The reported prevalence of COPD ranged from 2.6% to 52.7% in patients with schizophrenia and between 3.0% and 12.9% in patients with bipolar disorder. Two studies reported an annual incidence of COPD of 2.21 cases/100 person-years in patients with schizophrenia and 2.03 cases/100 person-years in patients with bipolar disorder. Among the risk factors evaluated in three studies, only advanced age was consistently associated with the presence/occurrence of COPD in patients with schizophrenia and bipolar disorder; the role of tobacco consumption was not investigated in those three studies. According to two studies, the likelihood of mortality from COPD showed an over 3-fold increase in patients with schizophrenia and a 2-fold increase in those with bipolar disorder compared to the overall population; COPD was also associated with increased inpatient mortality. Available data indicate that COPD in patients with schizophrenia and bipolar disorder is a major public health problem. National and international health organizations should strive to specifically address this issue by creating awareness about this health problem and developing specific programs for screening and early intervention aimed to reduce the burden of COPD in these populations.
一项系统综述旨在调查精神分裂症、双相情感障碍与慢性阻塞性肺疾病（COPD）之间的关联、其患病率和发病率、与其发生相关的潜在因素以及对这些患者死亡率的影响。我们在PubMed、Scopus和PsycInfo数据库中进行了从建库至2022年2月的文献检索，共识别出19项研究：10项横断面研究、5项包含横断面和纵向分析的研究以及4项回顾性队列研究。报告显示，精神分裂症患者中COPD的患病率在2.6%至52.7%之间，双相情感障碍患者中COPD的患病率在3.0%至12.9%之间。两项研究报告称，精神分裂症患者中COPD的年发病率为2.21例/100人年，双相情感障碍患者中COPD的年发病率为2.03例/100人年。在三项研究评估的风险因素中，只有高龄始终与精神分裂症和双相情感障碍患者中COPD的存在/发生相关；这三项研究未调查烟草消费的作用。根据两项研究，与总体人群相比，精神分裂症患者因COPD死亡的可能性增加了3倍多，双相情感障碍患者增加了2倍；COPD还与住院患者死亡率增加有关。现有数据表明，精神分裂症和双相情感障碍患者中的COPD是一个重大的公共卫生问题。国家和国际卫生组织应努力通过提高对这一健康问题的认识，并制定旨在减轻这些人群中COPD负担的筛查和早期干预具体项目，来专门解决这一问题。
